Topical Instillation of Resveratrol Preconditioned Wharton’s Jelly Mesenchymal Stem Cell Secretome Preserves Ocular Surface in Experimental Model of Severe Dry Eye Disease by Astaridewi, Diandra et al.
1116 https://www.id-press.eu/mjms/index
Scientific Foundation SPIROSKI, Skopje, Republic of Macedonia
Open Access Macedonian Journal of Medical Sciences. 2020 Oct 30; 8(B):1116-1123.
https://doi.org/10.3889/oamjms.2020.5305
eISSN: 1857-9655
Category: B - Clinical Sciences
Section: Ophtalmology
Topical Instillation of Resveratrol Preconditioned Wharton’s Jelly 
Mesenchymal Stem Cell Secretome Preserves Ocular Surface in 
Experimental Model of Severe Dry Eye Disease
Diandra Astaridewi1, Evelyn Komaratih1, Yuyun Rindiastuti1, Yohanes Widodo Wirohadidjojo2, Djoko Legowo3, 
Ni Made Inten Lestari1, Diandra Astari Dewi1, I. Made Satya1, Fedik A. Rantam4, Cita R. S. Prakoeswa5*
1Department of Ophthalmology, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General Academic Hospital, 
Surabaya, Indonesia; 2Department of Dermatovenerology, Faculty of Medicine, Universitas Gadjah Mada, Dr. Sardjito 
General Academic Hospital, Radioputro Building, Yogyakarta, Indonesia; 3Department of Pathology Anatomy, Faculty 
of Veterinary Medicine, Universitas Airlangga, Kampus C Mulyorejo, Surabaya, Indonesia; 4Stem Cell Research 
and Development Center, Universitas Airlangga, Tropical Disease Center Building, Kampus C Mulyorejo, Surabaya, 
Indonesia; 5Department of Dermatovenerology, Faculty of Medicine, Universitas Airlangga, Dr. Soetomo General 
Academic Hospital, Surabaya, Indonesia
Abstract
BACKGROUND: Secretome derived from Wharton’s jelly mesenchymal stem cells (WJ-MSC) has a beneficial effect 
for ocular surface regeneration; however, the high amount of vascular endothelial growth factor (VEGF) remains a 
challenge for its application.
AIM: The aim of the study was to investigate the effect of resveratrol (RV) (VEGF reducing agent) preconditioned 
WJ-MSC secretome in Concanavalin A-induced severe dry eye model.
METHODS: Pre- and post-experimental study composed of topical instillation of WJ-MSC secretome group, 
balanced salt solution control group, and normal control group. Tear production, tear break-up time (TBUT), corneal 
fluorescein dye staining, VEGF level in aqueous tear, goblet cell density, and inflammatory cells in the ocular surface 
were analyzed.
RESULTS: Topical instillation of RV preconditioned WJ-MSC secretome successfully improved tear film production 
(p = 0.008) and TBUT (p = 0.008), promoted goblet cell restoration (p = 0.023) and reduced corneal fluorescein 
staining (p = 0.003), while inhibited infiltration of inflammatory cells (p = 0.01) and secretion of VEGF in aqueous 
tear (p = 0.003).
CONCLUSION: Topical instillation of RV preconditioned WJ-MSC secretome has great potential as cell-free based 
therapy to preserve ocular surface in an experimental model of severe Dry eye disease.
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Introduction
Dry eye disease (DED) is an important public 
health problem that could hinder the performance 
of daily living activities, and therefore decreases 
the quality of life [1], [2] The inflammatory process in 
accordance with downregulation of growth factors such 
as epidermal growth factor (EGF), hepatocyte growth 
factor (HGF), and keratinocyte growth factor, while 
increasing of vascular endothelial growth factor (VEGF) 
leads to ocular surface damage in DED. VEGF-A, 
member of the cysteine superfamily plays a key role in 
corneal neovascularization [3], [4], [5], [6]. The mainstay 
therapy for DED is the application of artificial tears and 
topical anti-inflammatory or immunosuppressant that 
provides additional lubrication for the ocular surface 
and improves the symptoms of chronic inflammation. 
However, limited results and adverse ocular effects 
have been reported. In recent years, regenerative 
therapy has emerged a new strategy that promises an 
improvement in the management of DED [1], [2], [7].
Wharton’s jelly mesenchymal stem cells 
(WJ-MSC) are multipotent stem cells with the ability 
to differentiate into many mesoderm cell lineages. 
Investigation of MSC to treat immune-mediated 
disease has gained encouraging results [1], [2]. MSC 
transplantation has raised exciting expectations in 
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the treatment of DED and regeneration of the ocular 
surface damage [1], [3]. Immunomodulation as a basic 
therapeutic effect of stem cells is accomplished by the 
secreted bioactive factors that act as autocrine and 
paracrine effects in the term of cell secretome [8], [9]. 
The remain question in the management of dry eye 
using stem cells product is to elaborate the tolerable 
and effective MSC conditioned eye drop with low 
VEGF as the main of pro-angiogenic factor. Several 
attempts have been made to stimulate specific growth 
factors released by MSCs, such as manipulating 
culture with hypoxic condition, 3D culture system, and 
small molecule supplementation [1], [2]. Resveratrol 
(RV) is a small molecule phytoalexin agent, with a 
significant effect in reducing VEGF secretion in various 
cell lines [5], [6]. In this study, we adopted strategy by 
preconditioning MSC with RV to promote the secretion 
of EGF and HGF, while reducing VEGF secretion as the 
key growth factors for cell-free base therapy in DED. 
This study aimed to investigate the effects of topical 
instillation of RV preconditioned WJ-MSC secretome 
in the preservation of ocular surface in Concanavalin 
A-induced severe DED model.
Materials and Methods
Materials
Reagents included balanced salt solution 
(BSS) and Concanavalin A (ConA) from Sigma (St 
Louis, Missouri, USA). EGF, HGF, and VEGF-A 
enzyme-linked immunosorbent assay (ELISA) kit from 
Bioassay Technology Laboratory (Shanghai, China), 
hematoxylin-eosin (HE) from Merck (Massachusetts, 
USA), phycoerythrin (PE) conjugated antibodies against 
CD44, CD105, and CD45 and FACS Attune Acoustic 
Focusing Cytometer software from BD bioscience (New 
Jersey, USA). For the clinical experiment, we used 
Hamilton syringe with a 33-gauge needle (Hamilton, 
Reno, NV), Schirmer filter paper (Eye care products, 
India), fluorescein paper strip (Eye care products, 
India), portable slit lamp (KOWA SL-17, UK), light 
microscope from NIKON H600L with DS Fi32 300 
megapixel camera, and Canon digital camera (A2500, 
16 Megapixel).
Methods
Stem cell isolation and secretome production
Wharton’s jelly MSC was isolated from a single 
donor of umbilical cord, obtained from a healthy baby 
through caesarian section using the aseptic technique. 
The baby’s umbilical cord of length 3 cm was collected 
after the mother’s consent (ethical clearance number: 
1293/KEPK/VII/2019). Cells were isolated using the 
mixed enzymatic-explant method [10]. Cell pellets were 
suspended in a culture medium composed of α-MEM, 
1% penicillin-streptomycin, 1% amphotericin B, 1% 
non-essential amino acid (NEAA), 5% fetal bovine 
serum (FBS), and 5 ng/mL basic fibroblast growth 
factor, then stored in an incubator at 37°C and 5% CO2. 
Cell characterization was conducted using FACS flow 
cytometry using CD44, CD105, and CD45 antibody. A 
total amount of 5 × 103 cells/well of WJ-MSC at passage 
4 was cultured in 96 multiwall plate with culture media 
for 24 h to obtain 70% confluency. The cells treated for 
24 h using media composed of α-MEM, 1% penicillin-
streptomycin, 1% amphotericin B, 1% NEAA, and 
2% FBS supplemented with 0.1 µM RV after 70% of 
confluency was reached. The level of VEGF, EGF, and 
HGF in cell supernatant was measured using ELISA 
according to Bioassay Technology Laboratory protocol 
(Shanghai, China). The secretome was collected then 
filtered using 0.45 um Millipore filter, the osmolarity and 
acidity were adjusted for 270–300 mOsm/L and 7.2–
7.5, respectively. The secretome was packaged into 
a single-dose application in a sterile Eppendorf tube 
at 50 µl volume to avoid contamination and maintain 
the stability. The secretome was stored at −20°C until 
further application.
Animal model and treatment
All experiments were conducted with 
approval from the Animal Care and Use Committee, 
Faculty of Veterinary Medicine Universitas Airlangga 
(2.KE.099.05.2019). Three-month-old male New 
Zealand White Rabbits were purchased from The 
National Agency of Drug and Food Control of Republic 
Indonesia and maintained in a specific pathogen-free 
environment. The experiment was divided into three 
groups, including topical instillation of RV preconditioned 
WJ-MSC secretome group, BSS control group, and 
normal control group. The experiments were repeated 
in three independent experiments, and each of them 
included at least five rabbits per group. A total of 15 
male rabbits with bodyweight 2.5–3 kg were randomly 
assigned to one of three groups with five rabbits in each 
group. To create a severe DED model, we conducted 
resection of half parts of the inferior lacrimal gland and 
intraglandular injection of 300 µg ConA in 20 µL PBS 
using Hamilton syringe with a 33-gauge needle. Topical 
instillation of MSC secretome was administered every 
8 h for 7 days in the treatment group as well as topical 
instillation of BSS in BSS control group. No lacrimal 
gland manipulation and treatment were given in the 
normal control group.
Measurement of tear production using 
Schirmer tear test (STT)
Aqueous tear production was measured with 
standardized Whatman Schirmer paper. The paper was 
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inserted in the lateral cantus for 60 s and the length of 
wetting paper was measured in millimeters.
Tear break-up time (TBUT)
TBUT was determined by applying sodium 
fluorescein test strips onto the inferior conjunctival fornix, 
following which, the eyelids were opened and closed 
manually to distribute the fluorescein within the tear film. 
The eye was manually opened and the time between 
blink and appearance of first black spot in the pre-corneal 
tear film was observed under a portable slit lamp with 
cobalt blue illumination and recorded in second.
Corneal fluorescein dye staining
To evaluate the corneal epithelial integrity, 
corneal staining was performed by pre-wetted sodium 
fluorescein test strips onto the inferior lateral conjunctival 
sac. The corneal surface was observed in the portable 
slit lamp, cobalt blue light, and zoom 16 times. 
Photographs were taken with digital camera (Canon, 
A2500, 16 Megapixel), each image was coded to 
match pre- and post-treatment. The area of fluorescein 
staining was evaluated using Image J (v1.48) in 3 times 
by independent observer for the group assignment.
Histopathology
Enucleation procedure was performed to get 
the whole eyeball. The eyeball was stored in formalin 
and sliced in 4 µm and subjected to H&E staining. The 
histopathological section then examined in five different 
visual fields using Nikon H600L microscope under ×400 
magnification. Goblet cell density presented as mean of 
goblet cell density, the infiltration of the inflammatory cell 
was counted using Cell Count Nikon Image Systems 
and presented as mean of inflammatory cell.
Measurement of VEGF-A level in the tear 
film 
VEGF measurement was conducted to 
determine the angiogenic factor that was contained in 
aqueous tear result from the inflammatory condition of 
the ocular surface. VEGF was measured using VEGF-A 
ELISA kit according to the protocol from Bioassay 
Technology Laboratory, Shanghai, China. Briefly, 20 µL 
of aqueous tear was collected using 20 µL micropipette 
in lateral cantus region of the eye. A total amount of 
20 µl sample was placed into ELISA well plate, with 
biotinylated antibody and streptavidin HRP added and 
incubated at 37°C for 60 min. Sample was washed ×3 
with buffer, with solution A and B added and incubated 
at 37°C for 10 min. Finally, stop solution was added 
and the plate was read immediately using a microplate 
reader at an absorbance of 450 nm.
Statistical analysis
Statistical analyses regarding STT and TBUT 
data were Kruskal–Wallis test and Mann–Whitney post-
hoc test. The level of VEGF-A in aqueous tear, area 
of fluorescein dye staining, goblet cell density, and 
inflammatory cells was analyzed using one way ANOVA 
and Games-Howell post-hoc test. All of the results 
considered to be significant if p < 0.05.
Results
Stem cell secretome
We were successfully cultured cell population 
that fulfilled MSC criteria such as fibroblast-like 
formation, adhere to culture dish, positive for CD44 
and CD105, but negative for CD45 with flow cytometry 
analysis as depicted in Figure 1. RV at 0.1 µM promotes 
HGF secretion (250 ± 8 pg/mL) and EGF secretion 
(76.67 ± 15.67 pg/mL), while the VEGF secretion was 
quite low (65 ± 5.02 pg/mL).
Topical instillation of RV preconditioned 
WJ-MSC secretome increased tear production
The tear production was significantly 
increased after topical instillation of WJ-MSC 
secretome group (Table 1 and Figure 2). In addition, 
topical instillation of WJ-MSC secretome significantly 
improved TBUT score, indicating recovery of tear film 
stability (Table 1).
Table 1: Topical instillation of RV preconditioned WJ-MSC 
secretome improved tear production and TBUT
Time 
point
Group
WJ-MSC secretome BSS control Normal control
STT (mm) TBUT (s) STT (mm) TBUT (s) STT (mm) TBUT (s)
Day-0 4.10 ± 0.22 5.4 ± 0.54 4.0 ± 0.0 5.4 ± 0.57 21.2 ± 0.83 16.4 ± 0.54
Day-7 12.6 ± 0.89a,b 10.4 ± 1.14a,b 4.8 ± 0.83b 5.6 ± 0.54b 20.6 ± 0.89 17.0 ± 0.58
ap < 0.05 versus BSS control, bp < 0.05 versus normal control (Kruskal–Wallis, Mann–Whitney post-hoc 
test). WJ-MSC: Wharton’s jelly mesenchymal stem cell, BSS: Balanced salt solution, STT: Schirmer tear 
test, TBUT: Tear break-up time.
Topical instillation of RV preconditioned 
WJ-MSC secretome promoted regeneration of 
corneal epithelial cell
Before topical instillation of MSC secretome, 
all eyes had the same baseline profile of ocular 
surface conditions. After topical instillation of WJ-MSC 
secretome, ocular surface improvement in the treatment 
group was observed by day 7. This was shown by 
reduction into mild ciliary hyperemia without any corneal 
opacity and decreased of fluorescein dye staining area 
as the sign of corneal epithelial defect compare to the 
BSS control group (Figure 3 and Table 2).
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Topical instillation of RV preconditioned 
WJ-MSC secretome restored goblet cell in the 
conjunctiva
HE staining of the conjunctiva showed that the 
number of goblet cells which are responsible for mucous 
tear production was markedly decreased in BSS control 
group (0.84 ± 0.21 cells/visual field) (Figure 3). The 
conjunctival goblet cell count was significantly higher in 
the eyes with topical instillation of WJ-MSC secretome 
(2.4 ± 0.8 cells/visual field, p = 0.023) compared to the 
BSS control group. However, the restoration of goblet 
cell populations was markedly different from the normal 
control group (12.89 ± 2.99 cells/visual field, p = 0.002) 
(Figure 4 and Figure 5).
Topical instillation of RV preconditioned 
WJ-MSC secretome decreased infiltration of 
inflammatory cells in the ocular surface 
HE staining showed the highest infiltration of 
inflammatory cells, mainly neutrophil and lymphocytes 
in the BSS group (406.88 ± 117.09 cells/visual field). 
The treatment with topical instillation of WJ-MSC 
secretome (144.40 ± 56.92 cells/visual field, p = 0.01) 
0
5
10
15
20
25
30
35
40
45
WJ-MSC secretome BSS control Normal control
ST
T 
(m
m
)
Day-7
Day-0
0
5
10
15
20
25
30
35
40
WJ-MSC secretome BSS control Normal control
TB
U
T 
(s
ec
on
d)
Group
Day-7
Day-0
Group
Figure 2: STT and TBUT score among groups. The graphs showed 
the changes of STT and TBUT score before and after treatment. 
WJ-MSC: Wharton’s jelly mesenchymal stem cell, BSS: Balanced 
salt solution, STT: Schirmer tear test, TBUT: Tear break-up time
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Figure 1: Identification of CD44, CD105, CD45 cell population using flow cytometry, (a) cell positive for CD44 and CD105 (88.94–89.01%), 
(b) cell positive for CD45 and negative for CD44 (0.08%)
b
a
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markedly decreased the infiltration of inflammatory cells 
compared to BSS control group, in which neutrophil 
was the predominance inflammatory cell. We found 
that inflammatory cell in WJ-MSC secretome group was 
2.5 fold higher than the normal control group (58.88 ± 
20.01 cells/visual field, p = 0.055); however, it was not 
significant (Figure 5).
Figure 3: Topical instillation of RV preconditioned WJ-MSC secretome 
promoted corneal epithelial regeneration. Fluorescein dye staining 
in cornea at day-0: (a) WJ-MSC secretome group, (c) BSS control. 
Fluorescein dye staining in cornea at day-7: (b) WJ-MSC secretome 
group,  (d)  BSS  control.  WJ-MSC:  Wharton’s  jelly  mesenchymal 
stem cell, BSS: Balanced salt solution, Green staining: Fluorescein 
staining in corneal epithelial defect
dc
ba
Topical instillation of RV preconditioned 
WJ-MSC secretome reduced VEGF-A level in 
aqueous tear
The level of VEGF-A in aqueous tear was 
relatively similar at baseline between WJ-MSC 
secretome group and BSS control group. Topical 
instillation WJ-MSC secretome significantly reduced 
VEGF level (11.7 ± 2.79 pg/mL, p = 0.003) in aqueous 
Figure 4: Topical instillation of RV preconditioned WJ-MSC secretome 
restored corneal goblet cell density (arrow: Goblet cell). (a) WJ-MSC 
secretome group,  (b) normal control group,  (c) BSS control group. 
WJ-MSC: Wharton’s jelly mesenchymal stem cell, BSS: Balanced 
salt  solution.  (Hematoxylin-eosin staining, 400× magnification,  light 
microscope, Nikon H600L with DS Fi2 300 megapixel camera). Black 
bar: 100 µm
cba
Table 2: Mean area of fluorescein dye staining in cornea
Treatment group Fluorescein dye staining 
area Day-0 (Pixel)
Fluorescein dye staining 
area Day-7 (Pixel)
BSS control 7.92 × 105 ± 3.67 × 104 1.2 × 106 ± 8.51 × 104
WJ-MSC secretome 7.98 × 105 ± 2.09 × 104 1.92 × 105 ± 1.05 × 104a
ap < 0.05 versus BSS control group at 7 days after treatment (independent t-test). WJ-MSC: Wharton’s jelly 
mesenchymal stem cell, BSS: Balanced salt solution.
tear compared to the BSS control group (55.55 ± 
13.3 pg/mL) (Figure 5). However, the VEGF level still 
higher than the normal control group (5.05 ± 1.51 pg/mL, 
p = 0.009).
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Figure  5:  The  effect  of  topical  instillation  of  RV  preconditioned 
WJ-MSC secretome on goblet cell, infiltration of inflammatory cell in 
ocular surface, and vascular endothelial growth factor (VEGF)-A level 
in aqueous tear. (a) Goblet cell number, (b) inflammatory cell number, 
(c) VEGF-A level. WJ-MSC: Wharton’s jelly mesenchymal stem cell, 
BSS: Balanced salt solution. *p < 0.05 versus BSS control group
Discussion
To best of our knowledge, this is the first study 
conducted to develop the conditioned secretome using 
RV supplementation to decrease VEGF secretion. 
In this study, 0.1 µM RV was successfully to promote 
the secretion of EGF and HGF, while decreases 
the level of VEGF. The previous study revealed that 
conditioned media from retinal pigment epithelial (RPE) 
cells treated with RV has the ability to inhibit human 
umbilical vein endothelial cells tube formation. RV at 
50 µM concentration suppressed VEGF secretion in 
hypoxic RPE cells through inhibition of CXC-chemokine 
c
b
a
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receptor 4 [5], [6], [9], [10], [11]. This is the first study 
that investigated the therapeutic effect of the topical 
application of specifically manufactured stem cell 
secretome in severe DED model. A number of researches 
have already explored the effect of MSC secretome on 
corneal regeneration; however, this corneal defect was 
not co-exist with the presence of DED in which lacrimal 
gland dysfunction and inflammatory process are the 
main underlying pathologies [3], [9], [12], [13].
Our study revealed a significant improvement 
of tear production after topical instillation of RV 
preconditioned WJ-MSC secretome in the animal model 
of severe DED. The recovery of lacrimal gland function 
might be related to the immunomodulatory effect of 
the secreted product derived from WJ-MSC. However, 
the histological section of the lacrimal gland has yet to 
be evaluated in this study. Other study demonstrated 
that intraglandular transplantation of MSC reduced 
the infiltration of inflammatory cells in the intraorbital 
gland and ocular surface of the murine model of ConA-
induced inflammatory dry eye. Other study reported 
a significantly increased tear production and goblet 
cell number through the immunomodulatory effect of 
MSC without long-term engraftment. Evidence of no 
long-term engraftment indicated that MSC exerts their 
therapeutic potential by their paracrine effect of cell-
secreted factors [14], [15]. Single dose of allogeneic 
MSC transplantation in a dog with mild to moderate 
DED showed a significant increase in STT and ocular 
surface improvement in short- and long-term follow-up. 
However, an experimental study in a dog with severe 
DED revealed the improvement of STT and clinical 
sign without complete restoration of ocular surface 
status [16]. In another study, topical instillation of MSC 
in a week leads to an increase in aqueous tear volume 
and improvement in ocular surface evaluation tests in 
benzalkonium chloride-induced dry eye model in rats. 
The study reported that topical instillation of MSC 
might decrease inflammation, increase tear volume 
production and improve clinical appearance of the 
ocular surface [7].
We found an improvement of ocular 
surface inflammation after topical instillation of RV 
preconditioned WJ-MSC secretome. This clinical 
profile was in accordance with lower infiltration of 
inflammatory cells within conjunctiva and cornea that 
may describe the immunomodulatory effect of WJ-MSC 
secreted factors, mainly the anti-inflammation effect. 
The previous study stated that the innate and adaptive 
immune response is governed the immunomodulatory 
effect of MSC, through the secretion of different 
soluble substances in their secretome [17]. However, 
the exact immunomodulatory mechanism is yet to be 
elaborated [17], [18], [19], [20].
The chronic inflammatory condition of the ocular 
surface results in a gradual loss of conjunctival goblet 
cells [13], [14], [20]. Our study revealed that topical 
instillation of RV preconditioned WJ-MSC secretome 
successfully restored the goblet cell population 
compared to the control group. This result indicated a 
regenerative effect of WJ-MSC secretome on mucin-
producing cells within conjunctival tissue, as shown with 
the improvement of TBUT. The anti-inflammatory effect 
of WJ-MSC secretome contributes to suppressing the 
chronic inflammatory process in the ocular surface, 
thus restores the goblet cell population and function. 
Moreover, MSC administered to a murine model of 
DED protected the ocular surface by suppressing CD4+ 
T-cell infiltration and decreasing levels of inflammatory 
cytokines such as IL-2 and IFN-γ [21], [22], [23], [24].
In severe DED, there is damage to the 
corneal surface [13], [14]. Topical instillations of RV 
preconditioned WJ-MSC secretome successfully 
promoted corneal epithelial regeneration in this study. 
It might be related to the high amount of EGF and 
HGF level contained in secretome derived from RV 
preconditioned WJ-MSC. EGF is a key factor for corneal 
epithelial regeneration, the crosstalk between EGF and 
HGF may facilitate epithelial regeneration by modulating 
the inflammatory response. Some studies showed the 
advancement of corneal wound healing after instillation 
of secretome derived from MSC. Its application may 
attenuate corneal inflammation by inhibiting the pro-
inflammatory cytokines and infiltration of inflammatory 
cells [25], [26], [27]. The study described the effects of 
MSC secretome on ethanol induced-human corneal 
epithelial progenitor cells (hCEPs) injury, they found 
that MSC secretome enhanced survival, proliferation, 
and inhibited apoptosis of injured hCEPs [27]. A recent 
study reported significant improvement of corneal 
epithelial regeneration in the atropine-induced dry eye 
in rabbits after the administration of conditioned media 
derived from human uterine cervical epithelial stem cells 
(CM-hUCESC). Those studies showed that the corneal 
regenerative effect of stem cell conditioned media might 
be facilitated by decreasing corneal pro-inflammatory 
TNF-α, MCP-1, MIP-1α, and IL-6 cytokines. In 
addition, secretome derived from hUCESC showed 
the regenerative and anti-apoptosis effect in corneal 
epithelial cells through a high level of metalloproteinase 
inhibitors TIMP-1 and TIMP-2 [27], [28].
Corneal neovascularization is the hallmark 
of disease severity in chronic inflammatory DED. 
The increasing of VEGF-A in aqueous tear plays 
a key role in this neovascularization. The level of 
VEGF-A in aqueous tear was found to be lower in RV 
preconditioned WJ-MSC secretome group compared 
to BSS control group. Moreover, we did not find any 
growth of new vessels in both of histological section 
and ocular surface. However, MSC has been shown 
to be good activators of angiogenesis and secretes 
VEGF as the most potent angiogenic factor [29], [30]. 
In this study, we successfully decreased VEGF-A 
secretion from WJ-MSC culture with supplementation 
of 0.1 µM RV. Another study showed that intracameral 
injection of human amniotic (hAM)-MSC reduces 
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corneal neovascularization, opacity, and stromal 
infiltration of inflammatory cells [30]. Therefore, the 
effect of WJ-MSC secretome on the inhibition of corneal 
neovascularization need a longer time of observation 
and further exploration.
As limitation, we did not determine the exact 
mechanism of topical instillation of RV preconditioned 
WJ-MSC secretome that may contribute in the 
preservation ocular surface in experimental model 
of severe DED. However, our study may suggest the 
new insight to produce specific MSC secretome with 
low pro-angiogenic factor by supplementation of culture 
media with 0.1 µM RV.
Conclusion
In conclusion, the study has revealed that 
Topical instillation of RV preconditioned WJ-MSC 
secretome has great potential as cell-free based 
therapy to preserved ocular surface in experimental 
model of severe DED. The challenge for further animal 
and clinical trial is to establish MSC culture conditions to 
produce safe, tolerable, and effective MSC secretome 
in eye drops preparation.
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